MetaCap

Autolus Therapeutics (AUTL) vs Protalix BioTherapeutics (DE) (PLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Protalix BioTherapeutics (DE) (PLX) has outperformed Autolus Therapeutics (AUTL) over the past year, gaining 65.7% versus a loss of 26.2%. Over five years, PLX leads with a +192.9% price change compared with -85.5% for AUTL. Protalix BioTherapeutics (DE) is the larger company by market cap ($244.5 million vs $241.7 million), about 1.0 times the size, while Autolus Therapeutics is growing revenue faster (+644.9% vs -1.2%).

Protalix BioTherapeutics (DE) converts more of its revenue into profit, with a net margin of -12.5% versus -381.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-26.24%PLX+65.71%
+113%+40%-33%
Nov 21, 20251 yearNov 20, 2026
AUTL-85.41%PLX+195.92%
+250%+74%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus PLX key metrics
MetricAUTLPLX
Share price$0.9073$2.90
Market cap$241.65M$244.52M
1-day change-7.38%-5.23%
YTD return-54.41%+61.11%
1-year return-26.24%+65.71%
5-year return-85.51%+192.93%
P/E ratio (TTM)—12.08
Forward P/E—4.68
EPS (TTM)$-0.96$0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M$52.74M
Revenue growth (YoY)+644.94%-1.23%
Net income (latest FY)$-287.53M$-6.60M
Gross margin-27.83%48.82%
Operating margin-358.87%-10.43%
Net margin-381.40%-12.52%
52-week high$2.58$3.19
52-week low$0.896$1.65
Distance from 52-week high-64.83%-9.09%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+313.79%
Average volume2.07M903.48K
Shares outstanding266.34M84.32M
Employees752226
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLX has outperformed AUTL by 92.0 percentage points over the past year.
  • Protalix BioTherapeutics (DE) is more profitable, keeping -12.5 cents of every revenue dollar as net income versus -381.4 cents for Autolus Therapeutics.
  • Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs -1.23%).

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Protalix BioTherapeutics (DE)

PLX stock →

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees

AUTL vs PLX FAQ

Which is bigger, Autolus Therapeutics or Protalix BioTherapeutics (DE)?

Protalix BioTherapeutics (DE) (PLX) is larger, with a market capitalization of $244.52M compared with $241.65M for Autolus Therapeutics (AUTL).

Which stock has performed better over the past year, AUTL or PLX?

PLX returned +65.71% over the past 12 months, compared with -26.24% for AUTL (price return, excluding dividends). Past performance does not predict future results.

Are Autolus Therapeutics and Protalix BioTherapeutics (DE) in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons